Literature DB >> 15205328

Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.

Ruben Pio1, Isabel Zudaire, Irene Pino, Zafira Castaño, Natalia Zabalegui, Silvestre Vicent, Fermin Garcia-Amigot, Maria D Odero, Maria D Lozano, Jesus Garcia-Foncillas, Maria J Calasanz, Luis M Montuenga.   

Abstract

alpha CP-4 is an RNA-binding protein coded by PCBP4, a gene mapped to 3p21, a common deleted region in lung cancer. In this study we characterized the expression of alpha CP-4 and alpha CP-4a, an alternatively spliced variant of alpha CP-4, in lung cancer cell lines and non-small cell lung cancer (NSCLC) samples from early stage lung cancer patients. In NSCLC biopsies, an immunocytochemical analysis showed cytoplasmic expression of alpha CP-4 and alpha CP-4a in normal lung bronchiolar epithelium. In contrast, alpha CP-4 immunoreactivity was not found in 47% adenocarcinomas and 83% squamous cell carcinomas, whereas all of the tumors expressed alpha CP-4a. Besides, lack of alpha CP-4 expression was associated with high proliferation of the tumor (determined by Ki67 expression). By fluorescence in situ hybridization, >30% of NSCLC cell lines and tumors showed allelic losses at PCBP4, correlating with the absence of the protein. On the other hand, no mutations in the coding region of the gene were found in any of the 24 cell lines analyzed. By Northern blotting and real-time reverse transcription-PCR, we detected the expression of alpha CP-4 and alpha CP-4a messages in NSCLC and small cell lung cancer cell lines. Our data demonstrate an abnormal expression of alpha CP-4 in lung cancer, possibly associated with an altered processing of the alpha CP-4 mRNA leading to a predominant expression of alpha CP-4a. This may be considered as an example of alternative splicing involved in tumor suppressor gene inactivation. Finally, induction of alpha CP-4 expression reduced cell growth, in agreement with its proposed role as a tumor suppressor, and suggesting an association of this RNA-binding protein with lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205328     DOI: 10.1158/0008-5472.CAN-03-2982

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer.

Authors:  Fernando J de Miguel; María J Pajares; Elena Martínez-Terroba; Daniel Ajona; Xabier Morales; Ravi D Sharma; Francisco J Pardo; Ana Rouzaut; Angel Rubio; Luis M Montuenga; Ruben Pio
Journal:  Mol Oncol       Date:  2016-08-09       Impact factor: 6.603

2.  Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.

Authors:  Changmeng Cai; Chen-Lin Hsieh; Shuai Gao; Archana Kannan; Meenakshi Bhansali; Kumara Govardhan; Ranendra Dutta; Lirim Shemshedini
Journal:  Mol Endocrinol       Date:  2011-12-15

3.  Development of a novel splice array platform and its application in the identification of alternative splice variants in lung cancer.

Authors:  Ruben Pio; David Blanco; Maria Jose Pajares; Elena Aibar; Olga Durany; Teresa Ezponda; Jackeline Agorreta; Javier Gomez-Roman; Miguel Angel Anton; Angel Rubio; Maria D Lozano; Jose M López-Picazo; Francesc Subirada; Tamara Maes; Luis M Montuenga
Journal:  BMC Genomics       Date:  2010-06-03       Impact factor: 3.969

Review 4.  Poly(C)-binding proteins as transcriptional regulators of gene expression.

Authors:  Hack Sun Choi; Cheol Kyu Hwang; Kyu Young Song; Ping-Yee Law; Li-Na Wei; Horace H Loh
Journal:  Biochem Biophys Res Commun       Date:  2009-01-27       Impact factor: 3.575

Review 5.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

6.  Identification of novel deregulated RNA metabolism-related genes in non-small cell lung cancer.

Authors:  Iñaki Valles; Maria J Pajares; Victor Segura; Elisabet Guruceaga; Javier Gomez-Roman; David Blanco; Akiko Tamura; Luis M Montuenga; Ruben Pio
Journal:  PLoS One       Date:  2012-08-02       Impact factor: 3.240

7.  The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability.

Authors:  Ariane Scoumanne; Seong Jun Cho; Jin Zhang; Xinbin Chen
Journal:  Nucleic Acids Res       Date:  2010-09-03       Impact factor: 16.971

8.  Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC.

Authors:  Eva M Galan-Moya; Miguel A de la Cruz-Morcillo; Maria Llanos Valero; Juan L Callejas-Valera; Pedro Melgar-Rojas; Javier Hernadez Losa; Mayte Salcedo; Antonio Fernández-Aramburo; Santiago Ramon y Cajal; Ricardo Sánchez-Prieto
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

9.  High-throughput alternative splicing quantification by primer extension and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.

Authors:  Ron M McCullough; Charles R Cantor; Chunming Ding
Journal:  Nucleic Acids Res       Date:  2005-06-20       Impact factor: 16.971

10.  Novel function of the poly(c)-binding protein α-CP2 as a transcriptional activator that binds to single-stranded DNA sequences.

Authors:  Duk-Hee Kang; Kyu Young Song; Li-Na Wei; Ping-Yee Law; Horace H Loh; Hack Sun Choi
Journal:  Int J Mol Med       Date:  2013-09-11       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.